{"denoms":[{"counts":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"192"}],"units":"Participants"}],"groups":[{"description":"Patients receive induction therapy comprising oral dexamethasone (DM) on days 1-4, 9-12, and 17-20 and oral lenalidomide on days 1-28. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising oral DM on days 1-4 and 15-18 and oral lenalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Lenalidomide+Dexamethasone"},{"description":"Patients receive induction therapy comprising DM as in arm I induction and oral placebo on days 1-28. Treatment repeats as in arm I induction. Some patients may then receive maintenance therapy comprising oral DM as in arm I maintenance and oral placebo on days 1-21. Courses repeat as in arm I maintenance.","id":"BG001","title":"Dexamethasone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"36.9","upperLimit":"89.0","value":"64.9"},{"groupId":"BG001","lowerLimit":"37.6","upperLimit":"87.0","value":"63.1"},{"groupId":"BG002","lowerLimit":"36.9","upperLimit":"89.0","value":"64.6"}]}],"title":"Overall"}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"84"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"108"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}